PEOPLE - Magnisense makes appointment:
This article was originally published in Clinica
Clayton Pequignot, currently a partner at the US medical sector-focused company Venstrata Consulting, has been appointed by French immunoassays development firm Magnisense, as its US market business developer. In this role, Mr Pequignot will find partners for licensing products using the firm's proprietary technology. Magnisense bases its tech and IP development in Luxembourg City, and its business development in Paris.
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.